In Vivo is part of Informa PLC

This site is operated by a business or businesses owned by Informa PLC and all copyright resides with them. Informa PLC’s registered office is 5 Howick Place, London SW1P 1WG. Registered in England and Wales. Number 8860726.

This copy is for your personal, non-commercial use. For high-quality copies or electronic reprints for distribution to colleagues or customers, please call +44 (0) 20 3377 3183

Printed By

UsernamePublicRestriction
UsernamePublicRestriction

Tarceva Price Will Be Bounded By Iressa And Gleevec, OSI Says

This article was originally published in The Pink Sheet Daily

Executive Summary

The dose and pharmacokinetic profile of Tarceva allow for premium pricing over AstraZeneca's Iressa, OSI CEO Colin Goddard says. Approval of Tarceva for the treatment of non-small cell lung cancer possible by late January.

You may also be interested in...



Genentech/OSI Raise Tarceva Price 15% In Wake Of Iressa Failure

Genentech/OSI Raise Tarceva Price 15% In Wake Of Iressa Failure

Tarceva Sales Effort Will Be Led By Genentech; OSI To Provide 25% Of Reps

An amendment to the companies' 2001 Tarceva development and marketing agreement clarifies responsibilities for each party upon FDA approval of the oncologic. OSI will be responsible for manufacturing commercial supply; the company plans to outsource production to third parties.

Related Content

Topics

UsernamePublicRestriction

Register

SC142496

Ask The Analyst

Ask the Analyst is free for subscribers.  Submit your question and one of our analysts will be in touch.

Your question has been successfully sent to the email address below and we will get back as soon as possible. my@email.address.

All fields are required.

Please make sure all fields are completed.

Please make sure you have filled out all fields

Please make sure you have filled out all fields

Please enter a valid e-mail address

Please enter a valid Phone Number

Ask your question to our analysts

Cancel